Current Report Filing (8-k)
September 23 2016 - 11:55AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): September 23, 2016
Enhance
Skin Products Inc.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-52755
|
|
84-1724410
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
50
West Liberty Street, Suite 880, Reno NV
|
|
80246
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (416) 306--2493
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION
1 - REGISTRANT’S BUSINESS AND OPERATIONS
ITEM
1.01 - ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
September 23, 2016, the Company and Integumen Limited (“Integumen”) formerly Biosurface Limited entered into an agreement
amending the Option Agreement entered into by the parties on July 7, 2016 as amended July 29, 2016, August 12, 2016, August 24,
2016, September 1, 2016, September 8, 2016 and September 15, 2016 (the “Option Amendment Agreement”). The Option Amendment
Agreement extends the expiration date of the option in the Option Agreement from September 23, 2016 to September 28, 2016. All
other terms of the Option Agreement remain unchanged.
The
foregoing description of Option Amendment Agreement does not purport to be complete and is qualified in its entirety by reference
to the complete text of the foregoing document, which is filed as Exhibits 10.1 hereto, and which is incorporated herein by this
reference.
SECTION
9 – FINANCIAL STATEMENTS AND EXHIBITS
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS
10.1
|
Option Amendment
Agreement
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Enhance Skin Products Inc.
|
|
|
|
|
By:
|
/s/
Donald Nicholson
|
|
|
Donald Nicholson
|
|
|
President/CEO, Principal Executive Officer
|
Dated:
September 23, 2016